Key points are not available for this paper at this time.
We have developed a non-invasive imaging protocol for dual assessment of hypoxia and glucose uptake in tumours using oxygen-enhanced MRI and glucoCESL MRI, and test feasibility in GL261 glioblastoma and MOC2 head and neck cancer mouse models. GL261 tumours had a lower non-perfused fraction (p = 0.0015), a trend to higher glucose enhancing fraction (p = 0.07) and a smaller hypoxic glucose refractory fraction (p= 0.021). The normoxic glucose enhancing fraction was significantly larger than the normoxic glucose refractory fraction (p < 0.0001) in both models. These imaging tools will be used to assess the effects of hypoxia modifying drugs.
Dickie et al. (Wed,) studied this question.